German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany (C.S., D.W., T.G., S.J., N.N., M.M.v.B., M.B.S., C. Wittenbecher).
German Center for Diabetes Research (DZD), Neuherberg, Germany (C.S., S.J., A.F., M.B.S., C. Wittenbecher).
Circ Res. 2022 Sep 16;131(7):637-649. doi: 10.1161/CIRCRESAHA.122.321295. Epub 2022 Aug 26.
Despite mechanistic studies linking retinol and RBP4 (retinol binding protein 4) to the pathogenesis of cardiovascular diseases (CVD) and type 2 diabetes (T2D), epidemiological evidence is still conflicting. We investigated whether conflicting results of previous studies may be explained by differences in the association of retinol and RBP4 with cardiometabolic risk across subgroups with distinct sex, hypertension state, liver, or kidney function.
We used case-cohorts nested in the EPIC (European Prospective Investigation Into Cancer and Nutrition)-Potsdam cohort (N=27 548) comprising a random sample of participants (n=2500) and all physician-verified cases of incident CVD (n=508, median follow-up time 8.2 years) and T2D (n=820, median follow-up time 6.3 years). We estimated nonlinear and linear multivariable-adjusted associations between the biomarkers and cardiometabolic diseases by restricted cubic splines and Cox regression, respectively, testing potential interactions with hypertension, liver, and kidney function. Additionally, we performed 2-sample Mendelian Randomization analyses in publicly available data.
The association of retinol with cardiometabolic risk was modified by hypertension state ( interaction CVD<0.001; interaction T2D<0.001). Retinol was associated with lower cardiometabolic risk in participants with treated hypertension (hazard ratio [95% CI]: CVD, 0.71 [0.56-0.90]; T2D, 0.81 [0.70-0.94]) but with higher cardiometabolic risk in normotensive participants (CVD, 1.32 [1.06-1.64]; T2D, 1.15 [0.98-1.36]). Our analyses also indicated a significant interaction between RBP4 and hypertension on CVD risk ( interaction=0.04). Regarding T2D risk, we observed a u-shaped association with RBP4 in women ( nonlinearity=0.01, effect=0.02) and no statistically significant association in men. The biomarkers' interactions with liver or kidney function were not statistically significant. Hypertension state-specific associations for retinol concentrations with cardiovascular mortality risk were replicated in National Health and Nutrition Examination Survey III.
Our findings suggest a hypertension-dependent relationship between plasma retinol and cardiometabolic risk and complex interactions of RBP4 with sex and hypertension on cardiometabolic risk.
尽管有研究表明视黄醇和 RBP4(视黄醇结合蛋白 4)与心血管疾病 (CVD) 和 2 型糖尿病 (T2D) 的发病机制有关,但流行病学证据仍存在争议。我们研究了先前研究的结果是否存在差异,其原因可能是视黄醇和 RBP4 与不同性别、高血压状态、肝功能或肾功能的心血管代谢风险的相关性存在差异。
我们使用嵌套在 EPIC(欧洲癌症前瞻性调查和营养)-波茨坦队列中的病例-队列研究(N=27548),该队列包括参与者的随机样本(n=2500)和所有经医生确诊的 CVD(n=508,中位随访时间 8.2 年)和 T2D(n=820,中位随访时间 6.3 年)病例。我们使用限制性立方样条分别估计了生物标志物与心血管代谢疾病之间的非线性和线性多变量调整关联,并使用 Cox 回归进行了检验,以检测与高血压、肝功能和肾功能的潜在相互作用。此外,我们还在公开可用的数据中进行了两样本 Mendelian Randomization 分析。
视黄醇与心血管代谢风险的相关性受到高血压状态的调节(交互作用 CVD<0.001;交互作用 T2D<0.001)。在接受治疗的高血压患者中,视黄醇与较低的心血管代谢风险相关(CVD 风险比[95%CI]:0.71[0.56-0.90];T2D,0.81[0.70-0.94]),而在血压正常的参与者中,视黄醇与较高的心血管代谢风险相关(CVD,1.32[1.06-1.64];T2D,1.15[0.98-1.36])。我们的分析还表明,RBP4 与高血压对 CVD 风险的交互作用具有统计学意义(交互作用=0.04)。关于 T2D 风险,我们观察到 RBP4 与女性的 T2D 风险呈 U 型关联(非线性=0.01,效应=0.02),而男性则无统计学意义。生物标志物与肝功能或肾功能的相互作用无统计学意义。视黄醇浓度与心血管死亡率的高血压特异性相关性在国家健康与营养调查 III 中得到了复制。
我们的研究结果表明,血浆视黄醇与心血管代谢风险之间存在依赖于高血压的关系,并且 RBP4 与性别和高血压之间存在复杂的相互作用,对心血管代谢风险有影响。